Catalent (NYSE: CTLT) reported Q4 EPS of $1.16, $0.13 better than the analyst estimate of $1.03. Revenue for the quarter came in at $1.19 billion versus the consensus estimate of $1.14 billion.

“The past year has been extraordinary, for society and for our organization, during which we achieved great things, including building our infrastructure, growing our talent, deepening our long-standing commitment to sustainability practices, and accelerating our growth strategy,” said John Chiminski, Chair and Chief Executive Officer of Catalent, Inc. “We rose to the challenge of scaling our capacity to meet demand for vaccines and treatments to address the global COVID-19 pandemic, all while continuing to produce a broad range of important medicines under unprecedented circumstances. We are humbled to see the dedication of all our employees, who have allowed us to achieve this success. As we look ahead, we carry with us new knowledge, new capabilities, and strengthened partnerships, enabling us to continue to deliver products that ultimately allow people to live better, healthier lives.”

GUIDANCE:

Catalent sees FY2022 revenue of $4.3-4.5 billion, versus the consensus of $4.33 billion.

For earnings history and earnings-related data on Catalent (CTLT) click here.